FlandersBio on Twitter

Follow us on Twitter

Archive for October 2015 - News

Archive for October 2015 - Nieuws

in het nederlands in english

FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.

Immunovaccine’s Vaccine Candidate for Respiratory Syncytial Virus Is Well Tolerated in Patients in Phase 1 Clinical Trial

30.10.2015

Immunovaccine Inc. (“Immunovaccine” or the “Company”) (TSX: IMV; OTCQX: IMMVF), a clinical stage vaccine and immunotherapy company, today announced that safety data from a Phase 1 clinical study showed that its DepoVax™ prophylactic Respiratory Syncytial Virus vaccine candidate (“DPX-RSV”) was well tolerated in the Phase 1 study’s first 20 patients, of which 8 subjects received the DPX-RSV vaccine. This data marks an important milestone for Immunovaccine as it provides the first safety profile of the DepoVax™-based vaccines for infectious diseases in healthy adults. read more

argenx to Present at Key Investor Conferences in Q4

30.10.2015

argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that Chief Executive Officer, Tim Van Hauwermeiren and Chief Financial Officer, Eric Castaldi, will be participating in several upcoming investor conferences in November and December: read more

Genticel Announces First Patient Treated in U.S. Phase 1 Clinical Trial of GTL001, Company’s Therapeutic Vaccine Candidate against HPV 16/18 Infections

30.10.2015

Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a clinical-stage biotechnology company and developer of innovative immunotherapies to prevent cancers caused by the human papillomavirus (HPV), today announces that the first patient of the U.S. phase 1 clinical trial has been vaccinated with GTL001, the Company’s first-in-class therapeutic vaccine candidate against HPV 16/18 infections. read more

Ovizio partners with Pall Life Sciences to expand and commercialize the iLine S microscope range

29.10.2015

Ovizio Imaging Systems, an innovative microscopy company specializing in automated cell culture monitoring systems, and Pall Life Sciences, a global leader in biopharmaceutical fluid management, today announce the signing of a long term global supply agreement for the iLine S microscope. The financial terms of the agreement have not been disclosed. read more

UGent, UZ Gent en Janssen Pharmaceutica bouwen wetenschappelijke samenwerking uit

29.10.2015

De UGent, UZ Gent en Janssen Pharmaceutica gaan nauwer samenwerken op het vlak van innovatief onderzoek, om zo beter in te spelen op maatschappelijke en economische uitdagingen en medische innovaties sneller tot bij de patiënt te brengen. read more

GENTICEL : BUSINESS UPDATE – THIRD QUARTER 2015

29.10.2015

Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a clinical-stage biotechnology company and developer of innovative immunotherapies to prevent cancers caused by the human papillomavirus (HPV), today announced its cash & cash equivalents and liquid investments position and its highlights from the third quarter of 2015. read more

Complix to Present at CHI’s 7th Annual PEGS Europe Summit, November 5, 2015

28.10.2015

Complix, a biopharmaceutical company focused on the discovery and development of Alphabodies™, a novel class of protein therapeutics, announces that its CSO Dr Yvonne McGrath will present a talk entitled “Exploiting the Versatility of Alphabodies to Target the Intrinsic Pro-Survival Protein MCL-1”, at the CHI’s 7th Annual PEGS Europe Summit in Lisbon, Portugal (November 5). The talk will address the discovery and applications of Cell Penetrating Alphabodies (CPABs) active against a target in the intracellular space of cancer cells. Details of the presentation are listed below. read more

GSK Exercises Option on Oxford BioMedica’s LentiVector® Technology Patents

28.10.2015

Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: OXB), a leading gene and cell therapy group, announces that GlaxoSmithKline PLC (GSK) has exercised an option to obtain a non-exclusive licence for two rare orphan disease indications under Oxford BioMedica's LentiVector® platform technology patents. This follows an agreement signed between GSK and the Group in December 2013. read more

Simple blood test measures risk of liver cancer

27.10.2015

Researchers in Ghent have developed a test to measure the risk of liver cancer in people with cirrhosis of the liver. Their work will be revealed this week at United European Gastroenterology, the most important European conference for stomach, bowel and liver specialists. read more

List of key investors events Celyad will attend in the coming months

27.10.2015

Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, announces its participation in several financial conferences in the three coming months. During these events, the management team of Celyad will meet many institutional and retail investors to share with them the operational achievements made by the company during 2015 second half-year. read more

Join E-news

Interested in a regular update of the life sciences and biotech sector in Flanders? Subscribe to our newsletter.

Subscribe now

Back to top

Print